Galapagos' core value arises from the identification of novel protein targets and the discovery of better, disease-modifying small molecule drugs acting on these novel targets. Galapagos has a pipeline of four clinical, 6 pre-clinical, and >20 discovery stage drugs, most of which are based on novel modes of action identified by the Company.